CION Ameerpet
CAR T-cell therapy re-engineers your own immune cells to fight relapsed or refractory B-cell lymphoma. This guide explains how it works, who it suits, its risks, and how CION coordinates safe access through accredited partner facilities for patients across Hyderabad.
CAR T-cell therapy is a form of cellular immunotherapy that turns your own immune cells into a targeted treatment against lymphoma. Doctors collect T-cells — a type of white blood cell — from your blood, then re-engineer them in a specialised laboratory to carry a chimeric antigen receptor (CAR). This receptor is designed to lock onto a marker on the surface of the lymphoma cell, most often CD19 in B-cell lymphomas. The modified cells are grown in large numbers and infused back, where they multiply and attack the cancer.
Unlike a daily tablet or a repeated drip, CAR-T is a highly specialised, largely one-time living-cell treatment. It has become an important option for people whose aggressive B-cell lymphoma — such as diffuse large B-cell lymphoma (DLBCL) — has relapsed or has not responded to standard treatment. It sits within the wider family of immunotherapy and monoclonal antibody approaches, but works quite differently from an infused antibody.
Because it demands specialised manufacturing and intensive monitoring, CAR-T is delivered only at accredited cellular-therapy centres. CION's role is coordinated care: we assess whether you are a candidate, refer you to an accredited partner facility, and manage your lymphoma before and after. For the full picture of options, start with our Lymphoma hub and Lymphoma Treatment in Hyderabad.
CAR T-cell therapy targets a specific marker on the lymphoma cell — for most B-cell lymphomas this is CD19. Because the engineered cells go on multiplying inside the body after infusion, they are sometimes described as a "living drug." International guidelines from NCCN and ESMO now recognise CAR-T as a standard option for relapsed or refractory large B-cell lymphoma after earlier lines of treatment. (Source: NCCN B-cell Lymphomas guideline and ESMO clinical practice guidelines for diffuse large B-cell lymphoma.)
CAR-T is not a first treatment — standard chemo-immunotherapy comes first. It is considered when lymphoma comes back or proves resistant, and when the specific criteria below are met. A specialist assessment always decides suitability.
The best-established use is aggressive B-cell lymphoma — especially DLBCL — that has relapsed after, or not responded to, earlier treatment. Our page on relapsed or refractory DLBCL — what next explains exactly where CAR-T fits in the pathway.
Under NCCN and ESMO guidance, CAR-T is also an option for some cases of follicular lymphoma and mantle cell lymphoma that have progressed after multiple lines of treatment. Your subtype and prior treatment history guide the decision.
The lymphoma cells must carry the marker the CAR cells are built to attack (commonly CD19). This is confirmed on your pathology and immunophenotyping — testing concepts that CION delivers and reviews directly.
Because CAR-T involves lymphodepleting chemotherapy and a period of intensive monitoring, adequate organ function and overall fitness matter. Where CAR-T is not suitable, options such as stem cell transplant or a clinical trial may be considered instead.
Eligibility is individual and decided by a specialist team, in line with current NCCN and ESMO recommendations. This page is educational and not a substitute for a personalised assessment.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
If your lymphoma has come back or not responded to earlier treatment, CION's team can assess whether CAR T-cell therapy fits — and coordinate access if it does.
From the first assessment to recovery, CAR-T follows a clear sequence. The engineering and infusion happen at an accredited cellular-therapy facility; CION coordinates the referral, timing and the care that surrounds it.
| Step | What happens | Roughly how long |
|---|---|---|
| 1. Collection | T-cells are separated from your blood through leukapheresis | A few hours, outpatient |
| 2. Engineering | Cells are modified to carry the chimeric antigen receptor and multiplied in a specialised lab | ~2 to 4 weeks |
| 3. Lymphodepletion | A short course of chemotherapy prepares the body to receive the new cells | A few days before infusion |
| 4. Infusion | The engineered CAR T-cells are returned through a drip and begin to multiply and attack the lymphoma | Single infusion |
| 5. Monitoring | Close observation for side effects such as CRS and neurological effects, plus blood-count recovery | ~2 to several weeks |
Timelines are general and vary by product, facility and individual. While cells are being manufactured, CION keeps your lymphoma controlled with bridging treatment as needed. If you would like to know what a chemo / immunotherapy infusion or a chemo port or central line involves, we explain those separately.
CAR-T is powerful, and its side effects are specific and well-recognised — which is exactly why it is delivered only where teams are trained to spot and treat them early.
Most reactions occur in the first days to a couple of weeks after infusion, which is why the intensive monitoring window matters. Your specialist will weigh these risks against the potential benefit for your specific case. This is coordinated through the accredited partner facility, with CION managing your continuing lymphoma care.
CAR-T is now available in India at a small number of accredited cellular-therapy and transplant centres, including through an indigenously developed product that has made access more feasible than when only imported options existed. CION does not manufacture or infuse CAR-T in-house — it is a coordinated referral to an accredited partner facility. For a realistic sense of what is involved financially, see CAR T-cell therapy cost in India.
In relapsed or refractory aggressive B-cell lymphoma, CAR-T has produced meaningful, durable remissions in a proportion of people who previously had few options. Published trial series report that a substantial share achieve a complete response, with a meaningful subset remaining in remission long-term — though results vary by subtype, prior treatment and individual factors, and not everyone responds. For broad context, published survival figures across all patients are often quoted around 80–90% for Hodgkin lymphoma and roughly 60–70% for DLBCL (figures vary by individual and are not CAR-T-specific). Your specialist will give you a personalised, evidence-led picture in line with NCCN and ESMO guidance.
CAR-T is one of several routes for lymphoma that has come back. Depending on your case, the team may also consider autologous stem cell transplant, allogeneic (donor) transplant, bispecific antibodies, targeted therapy, involved-site radiation therapy or a clinical trial. The relapsed or refractory lymphoma pathway is decided by a tumour board.
CION reviews your diagnosis and prior treatment, confirms whether CAR-T fits, arranges the referral, and manages the care around it — chemotherapy, immunotherapy, targeted therapy, monitoring and survivorship are all delivered directly by our team. To begin, meet our best lymphoma doctors in Hyderabad at the best lymphoma hospital in Hyderabad.
A conversation about CAR-T — or a second opinion — is especially worthwhile if:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's team — we'll review your reports and tell you honestly whether CAR-T, transplant, bispecifics or a trial fits your situation.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.CAR T-cell therapy is a form of cellular immunotherapy that reprogrammes a person's own immune cells to recognise and destroy lymphoma. A sample of T-cells is collected from the blood, engineered in a specialised laboratory to carry a chimeric antigen receptor (CAR) that targets a marker on the lymphoma cell surface (most commonly CD19 in B-cell lymphomas), then grown in large numbers and infused back into the patient. Because it is a highly specialised, one-time living-cell treatment, CAR-T is delivered at accredited transplant and cellular-therapy centres. At CION we coordinate the full pathway — assessment, referral to an accredited partner facility, and follow-up care — so patients from Hyderabad can access it safely. Learn more on our Lymphoma Treatment in Hyderabad page.
CAR-T is generally considered for people whose aggressive B-cell lymphoma — such as diffuse large B-cell lymphoma (DLBCL) — has come back or has not responded to earlier lines of treatment. Under NCCN and ESMO guidance, it is an established option for relapsed or refractory large B-cell lymphoma and for some follicular and mantle cell lymphomas. Eligibility depends on the lymphoma subtype, the target marker (usually CD19) being present, adequate organ function, and fitness to withstand the process. It is not a first treatment; standard chemo-immunotherapy comes first. A specialist assessment decides suitability. If your lymphoma has relapsed, our page on relapsed or refractory DLBCL — what next explains where CAR-T fits.
There are four broad steps. First, collection: T-cells are separated from the blood through a process called leukapheresis. Second, engineering: in a specialised laboratory the cells are modified to express the chimeric antigen receptor and multiplied over roughly two to four weeks. Third, lymphodepletion: a short course of chemotherapy prepares the body to receive the new cells. Fourth, infusion: the engineered CAR T-cells are returned through a drip, after which they multiply inside the body and attack the lymphoma. Patients are then monitored closely for a period for side effects. The engineering and infusion happen at an accredited cellular-therapy facility; CION coordinates the referral, timing and wrap-around care.
Yes. CAR-T (cart therapy for dlbcl and other eligible B-cell lymphomas) is now available in India at a small number of accredited cellular-therapy and transplant centres, including through an indigenously developed product, which has made access more feasible than when the only options were imported. CION does not manufacture or infuse CAR-T in-house — it is a coordinated referral to an accredited partner facility. What CION provides is the specialist assessment of whether you are a candidate, help understanding the pathway and timelines, coordination of the referral, and continuity of your lymphoma care before and after. For a sense of what is involved financially, see CAR T-cell therapy cost in India.
The two most talked-about side effects are cytokine release syndrome (CRS) — an immune over-reaction that can cause fever, low blood pressure and breathing difficulty — and neurological effects (sometimes called ICANS) such as confusion or difficulty speaking. Both are usually temporary and are managed with supportive care and specific medicines at the treating centre, which is why CAR-T is delivered only where teams are trained to recognise and treat them early. Other effects include a drop in blood counts and a higher infection risk for a period. Most reactions occur in the first days to a couple of weeks after infusion, so close monitoring during that window is essential. These risks are weighed against the potential benefit during your specialist assessment.
CAR-T has produced meaningful, durable remissions in a proportion of people with relapsed or refractory aggressive B-cell lymphoma who had few options before. Published trial series report that a substantial share achieve a complete response, and a meaningful subset remain in remission long-term — though results vary by lymphoma subtype, prior treatment and individual factors, and not everyone responds. It is best described as a potentially long-lasting remission for some, rather than a guaranteed cure for all. For context, published survival figures for lymphoma overall are often quoted around 80–90% for Hodgkin lymphoma and roughly 60–70% for DLBCL across all patients (figures vary by individual). Your specialist will give you a realistic, personalised picture based on your case and current NCCN/ESMO evidence.
CION acts as your coordinating team. We review your diagnosis, pathology and prior treatment; confirm whether CAR-T (or another option such as stem cell transplant, bispecific antibodies or a clinical trial) fits your situation; and if CAR-T is appropriate, arrange referral to an accredited partner facility that delivers it. We help you understand timelines and costs, keep your lymphoma controlled while cells are being made, and manage your follow-up and survivorship care afterwards. Chemotherapy, immunotherapy, targeted therapy and monitoring that bridge the process are delivered directly by CION. To begin, book a free consultation or call 1800 202 8726.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.